Keloid Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Compression Therapy, Intralesional Corticosteroid Injections, Occlusive Dressing, Excision, Cryosurgery, Laser Therapy, Radiation Therapy, Interferon Therapy), By End User (Hospitals, Beauty Centres, Dermatology Clinics, Others) and Region Forecast 2020-2031

Keloid Treatment Market size was valued at US$ 3.9 billion in 2024 and is expected to reach US$ 4.9 billion by 2031, growing at a significant CAGR of 3.5% from 2025-2031. A keloid is an overgrown scar that rises beyond the skin's surface as a result of the creation of extra scar tissue on the healed skin area following surgery, a burn, or an injury. Keloids are most commonly found on the hands, legs, and neck, but they can appear anywhere. Although the exact cause of keloids is unknown, numerous factors such as age, gender, blood group, type of lesion, anatomical site, number of sites wounded, and family history can all play a role in identifying the cause. Other factors that may contribute to keloid formation and in predicting keloid behavior during diagnosis or therapy include delayed wound healing and hypertension. Excess of a protein in one's skin during the curing process after an injury causes a raised scar, which is known as keloid.

Keloid treatment greatly helps to flatten, soften, and North America stretch and shrink film the keloid as they are tough to get rid of entirely. Healthcare experts generally give combination treatment to obtain high treatment efficiency rates. Keloid scar can reduce over a period. Keloid scars are generally found in people of age group 10-30 years Keloid scar cases are hugely seen in Asian, African as well as American People. Acquisitions, mergers, collaborations and new product introduction are some of the effective strategies followed by the industries of the market in order to strengthen their place in the market.  Key players in this market are also bringing new technologies into the market. An abnormal proliferation of scar tissue that farms at the site of cutaneous injury is called a keloid. Keloid scar doesn't regress and progress beyond the scar's original margin and it can reduce over a period of time. Keloids are benign fibroproliferative dermal tumors.  

Key Developments

• On October 22, 2024 - Researchers in the UCT Hair and Skin Research Laboratory (HSR) have developed a promising new method to treat keloid disease (KD), a challenging skin scarring condition resulting from dermal (skin) injuries in keloid-prone individuals. The innovative approach taken by the HSR Lab involves using a targeted combination therapy designed to address uniquely identified keloid biomarkers. The treatment involves administering active compounds which are known for their role in inhibiting certain cellular processes.
• In 2024, NZX Limited has added a project to their R&D pipeline stating a topical treatment for keloid scars licensed from New Zealand’s Massey Ventures